The U.S. Food and Drug Administration (FDA) delayed a decision on whether to approve Moderna’s CCP virus vaccine for children aged 12 and older, according to the pharmaceutical giant on Sunday. The health regulator is investigating the risk of myocarditis, a form of heart inflammation, in children aged 12 to 17, Moderna’s statement said. The review may not be completed before January of next year, the company said. “The company is fully committed to working closely with the FDA to support their review and is grateful to the FDA for their diligence,” Moderna said, while adding that the “safety of vaccine recipients is of paramount importance to Moderna.” Moderna added it would delay filing a request for an emergency use authorization for a smaller dose of its mRNA vaccine among children aged 6 to 11. Late last week, the FDA granted emergency use authorization of pharmaceutical giant Pfizer’s COVID-19 vaccine for …